sumatriptan has been researched along with mk 3207 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantor, GH; Chaturvedula, PV; Conway, CM; Davis, C; Denton, R; Dubowchik, GM; Keavy, D; Macci, R; Macor, JE; Mathias, N; Mercer, SE; Moench, P; Pin, SS; Schartman, R; Signor, L; Thalody, G; Whiterock, V; Xu, C | 1 |
| Bell, IM | 1 |
1 review(s) available for sumatriptan and mk 3207
| Article | Year |
|---|---|
Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
Topics: Amino Acid Sequence; Animals; Calcitonin Gene-Related Peptide; Calcitonin Gene-Related Peptide Receptor Antagonists; Clinical Trials as Topic; Drug Discovery; Humans; Migraine Disorders; Molecular Sequence Data; Receptors, Calcitonin Gene-Related Peptide; Structure-Activity Relationship | 2014 |
1 other study(ies) available for sumatriptan and mk 3207
| Article | Year |
|---|---|
Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migr
Topics: Administration, Intranasal; Amides; Animals; Caco-2 Cells; Calcitonin Gene-Related Peptide Receptor Antagonists; Callithrix; Coronary Vessels; Drug Evaluation, Preclinical; Face; Humans; Indazoles; Migraine Disorders; Quinolones; Rabbits; Rats; Receptors, Calcitonin Gene-Related Peptide; Respiratory Mucosa | 2013 |